Overview

A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine

Status:
Completed
Trial end date:
2017-07-25
Target enrollment:
Participant gender:
Summary
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only). This Phase 1b cocaine interaction study is being conducted in order to assess the safety and PK of EMB-001 and cocaine in combination.
Phase:
Phase 1
Details
Lead Sponsor:
Embera NeuroTherapeutics, Inc.
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Cocaine
Metyrapone
Oxazepam